Company Overview and News

 
Brian Gaynor: Listed firms require right formula to fly

2017-12-08 nzherald.co.nz
The NZX/ASX listing debate has raised questions about the performance of New Zealand companies listed on the ASX.

 
Brian Gaynor: Focused a2 shows how it's done, who's next?

2017-11-24 nzherald.co.nz
The rise and rise of a2 Milk has been one of the NZX's most exciting stories.

 
Living Cell faces slower road to commercialisation after trial needs more analysis

2017-11-10 nzherald.co.nz
ASX-listed Kiwi biotech firm Living Cell Technologies won't seek provisional consent for its treatment for Parkinson's disease after the latest trial did not show a "statistically significant difference" between people who received the treatment and those who didn't.

 
Living Cell Technologies' shares slump 85% at the open

2017-11-09 proactiveinvestors.com.au
Living Cell Technologies Ltd's (ASX:LCT) shares have plunged 85.4% to $0.03 on heavy volume in the first 15 minutes of trade, following the top-line results of the company's Parkinson’s trial.

 
Living Cell Technologies maps timeline to clinical results from Parkinson's trial

2017-11-09 proactiveinvestors.com.au
Living Cell Technologies Ltd (ASX:LCT) is preparing some highly anticipated results from the NTCELL Parkinson's disease clinical trial, which are expected on Friday 10th November 2017.

 
Living Cell Technologies in trading halt pending Parkinson's trial result

2017-11-09 nzherald.co.nz
ASX-listed Kiwi biotech firm Living Cell Technologies is in a trading halt until tomorrow when it expects to announce the results of a clinical trial testing its treatment for Parkinson's disease.

 
Living Cell Technologies files patent for neurological agent

2017-11-07 proactiveinvestors.com.au
Living Cell Technologies Ltd (ASX:LCT) has filed a provisional patent for pericyte (a type of cell) protective agents for neurological disorders including neurodegenerative and central nervous system diseases.

 
Living Cell Technologies: Impending Phase IIb Results For NTCELL, A Disease-Modifying Agent For Parkinson's

2017-09-25 seekingalpha
NTCELL had disease modifying treatment effect equivalent to reversal of 2.8-3.5 years of neurological deterioration in Phase I/IIa trial at 81 weeks post implantation.

 
Living Cell Technologies’ patent application published in the U.S.

2017-01-11 proactiveinvestors.com.au
The choroid plexus is a plexus of cells that produces the cerebrospinal fluid in the ventricles of the brain. The published application recognises a significant number of claims relating to Living Cell’s lead product, NTCELL. NTCELL is a microcapsule which functions as a biological factory, producing factors to promote central nervous system growth and repair disease-induced nerve degeneration. The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease has met the primary endpoint of safety and reversed progression of the disease two years after implant.

 
Living Cell Technologies making progress in Parkinson’s treatment

2016-12-22 proactiveinvestors.com.au
NTCELL is a microcapsule which functions as a biological factory, producing factors to promote central nervous system growth and repair disease-induced nerve degeneration. Four patients in the trial had 80 NTCELL microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no NTCELL implanted. To date, there are no safety issues in any of the six patients.

 
Reversal Of Neurological Deterioration In Parkinson's Disease With NTCELL

2016-12-05 seekingalpha
NTCELL had disease modifying treatment effect equivalent to reversal of 2.8-3.5 years of neurological deterioration in Phase I/IIa trial at 81 weeks post implantation.

 
Living Cell Technologies Ltd in an ASX trading halt

2016-11-23 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Monday 28th November 2016, or earlier if an announcement is made to the market.

 
Living Cell Technologies Ltd advancing clinical trial for Parkinson’s

2016-10-07 proactiveinvestors.com.au
Living Cell Technologies Ltd (ASX:LCT) has completed treatment of all six patients in group 1 of the Phase IIb clinical trial of NTCELL for Parkinson’s disease, at Auckland City Hospital. NTCELL is a microcapsule which functions as a biological factory, producing factors to promote central nervous system growth and repair disease-induced nerve degeneration. Four patients in the trial had 40 NTCELL microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no NTCELL implanted.

 
Living Cell Technologies Ltd advancing clinical trial for Parkinson’s

2016-10-05 proactiveinvestors.com.au
Living Cell Technologies Ltd (ASX:LCT, OTCQX:LVCLY) is focused on discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 
Parkinson's Disease Pipeline Report Covering 179 Companies

2016-08-01 prnewswire
ReportnReports.com adds "Parkinson's Disease - Pipeline Review, H1 2016" market research report that provides an overview of the Parkinson's Disease's therapeutic pipeline with comprehensive information on the therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...